![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes
Differences in tumor biology, genomic architecture, and health care delivery patterns contribute to the breast cancer mortality gap between White and Black patients in the US. Although this gap has been well d...
-
Article
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015
Capecitabine is important in breast cancer treatment but causes diarrhea and hand-foot syndrome (HFS), affecting adherence and quality of life. We sought to identify pharmacogenomic predictors of capecitabine ...
-
Article
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
Sexual dysfunction is an important concern of premenopausal women with early breast cancer. We investigated predictors of sexual problems in two randomized controlled trials.
-
Article
Open AccessGlucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association
Non-ER nuclear receptor activity can alter estrogen receptor (ER) chromatin association and resultant ER-mediated transcription. Consistent with GR modulation of ER activity, high tumor glucocorticoid receptor...
-
Article
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors
Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse effects. We conducted a pilot study to test this hypothesis.
-
Article
Open AccessA randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer
Glucocorticoid receptor (GR) overexpression is associated with poor prognosis ER-negative breast cancer. GR antagonism with mifepristone increases chemotherapy-induced breast cancer cell death, therefore we co...
-
Article
Open AccessAdjuvant ovarian function suppression and cognitive function in women with breast cancer
To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer.
-
Article
Adjuvant Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer in Premenopausal Patient: Understanding the Data
Breast cancer diagnosed at a young age is associated with a poor prognosis. It is possible that inadequate endocrine therapy for the youngest women contributes to their poorer prognosis. Data on optimal endocr...
-
Article
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
The SOFT and TEXT randomized phase III trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) early breast cancer. We investigated the prognostic and pre...
-
Article
Open AccessCircadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion
Varying the rate of continuous intravenous infusions of 5-fluorouracil (5FU) chemotherapy over a 24-hour period has been reported to improve patient outcomes. It has been hypothesized that circadian variation ...
-
Article
Open AccessFactors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer
Studies have demonstrated lower rates of breast cancer survival for Black versus White women. Factors implicated include later stages at diagnosis, differences in tumor biology, and lower compliance rates to a...
-
Article
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
The mammalian target of rapamycin (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is ...
-
Article
Phase II trial of temsirolimus in patients with metastatic breast cancer
Preclinical models suggested that activating mutations of the PIK3CA gene are associated with sensitivity to inhibitors of the mammalian target of rapamycin (mTOR). In breast cancers, PIK3CA mutations are associa...
-
Article
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
Trastuzumab mediates the lysis of HER2-expressing breast cancer cell lines by interleukin-2 (IL-2) primed natural killer (NK) cells. We hypothesized that IL-2 would augment the anti-tumor effects of trastuzuma...
-
Chapter
Treatment of Advanced and Recurrent Carcinoma: Chemotherapy
The development of chemotherapy in endometrial cancer took place over two decades, but finally drug combinations have convincingly been shown to have a role in the treatment of advanced and recurrent endometri...
-
Article
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer
Etoposide is a widely used cytotoxic drug that is commercially available in both intravenous and oral formulations. High interpatient pharmacokinetic variability has been associated with oral etoposide adminis...
-
Article
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer
Carboxyamidotriazole (CAI) is a novel antineoplastic agent in clinical development with limited oral bioavailability. In vitro, ketoconazole has been demonstrated to inhibit CYP3A4-mediated metabolism of CAI. ...
-
Article
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment
Abstract
-
Article
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil
Aims: To determine the effect of food on the pharmacokinetics of 5-fluoruracil (5-FU) taken orally with eniluracil and to compare the performance of different pharmacokinetic analysis methods in the detection a p...
-
Article
Expedition inspiration consensus 2001